Skip to main content

Cancer Immunology, Immunotherapy

Ausgabe 10/2020

Inhalt (21 Artikel)

Editorial

Are we ready to use TMB in breast cancer clinical practice?

Sara Ravaioli, Francesco Limarzi, Maria Maddalena Tumedei, Michela Palleschi, Roberta Maltoni, Sara Bravaccini

Review

Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation

Charlotte Couchoud, Philippe Fagnoni, François Aubin, Virginie Westeel, Tristan Maurina, Antoine Thiery-Vuillemin, Claire Gerard, Marie Kroemer, Christophe Borg, Samuel Limat, Virginie Nerich

Original Article

Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer

Adele M. Barr, Anabel Silva, Sandro Prato, Gabrielle T. Belz, Eugene Maraskovsky, Adriana Baz Morelli

Open Access Original Article

Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer

Reem Saleh, Rowaida Z. Taha, Salman M. Toor, Varun Sasidharan Nair, Khaled Murshed, Mahwish Khawar, Mahmood Al-Dhaheri, Mahir Abdulla Petkar, Mohamed Abu Nada, Eyad Elkord

Open Access Original Article

Integrity of plasma DNA is inversely correlated with vaccine-induced antitumor immunity in ovarian cancer patients

Kayoko Waki, Kanako Yokomizo, Kouichiro Kawano, Naotake Tsuda, Nobukazu Komatsu, Akira Yamada

Open Access Original Article

The effects of tumor resection and adjuvant therapy on the peripheral blood immune cell profile in patients with colon carcinoma

Daniëlle Krijgsman, Natasja L. De Vries, Morten N. Andersen, Anni Skovbo, Rob A. E. M. Tollenaar, Esther Bastiaannet, Peter J. K. Kuppen, Marianne Hokland

Original Article

Prevention of liver metastases through perioperative acute CpG-C immune stimulation

Liat Sorski, Rivka Melamed, Ben Levi, Pini Matzner, Hagar Lavon, Ella Rosenne, Lee Shaashua, Itay Ricon, Elad Sandbank, Amit Benbenishty, Shamgar Ben-Eliyahu

Original Article

Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report

Hirofumi Utsumi, Jun Araya, Keitaro Okuda, Junko Watanabe, Daisuke Takekoshi, Yu Fujita, Mitsuo Hashimoto, Hiroshi Wakui, Shunsuke Minagawa, Takanori Numata, Hiromichi Hara, Kazuyoshi Kuwano

Original Article

Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma

Ryosuke Jikuya, Takeshi Kishida, Masahiko Sakaguchi, Tomoyuki Yokose, Masato Yasui, Akihito Hashizume, Tomoyuki Tatenuma, Nobuhiko Mizuno, Kentaro Muraoka, Susumu Umemoto, Masaki Kawai, Mitsuyo Yoshihara, Yoshiyasu Nakamura, Yohei Miyagi, Tetsuro Sasada

Original Article

Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor

Valentine Suteau, Alexandre Collin, Philippe Menei, Patrice Rodien, Marie-Christine Rousselet, Claire Briet

Open Access Original Article

Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion

Ellyn Hughes, Sarah N. Lauder, Kathryn Smart, Anja Bloom, Jake Scott, Emma Jones, Michelle Somerville, Molly Browne, Andrew Blainey, Andrew Godkin, Ann Ager, Awen Gallimore

Original Article

Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy

Jacques Rouanet, Valentin Benboubker, Hussein Akil, Ana Hennino, Philippe Auzeloux, Sophie Besse, Bruno Pereira, Solène Delorme, Sandrine Mansard, Michel D’Incan, Françoise Degoul, Paul-Olivier Rouzaire

Original Article

PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas

Mario Sanchez-Canteli, Rocio Granda-Díaz, Nagore del Rio-Ibisate, Eva Allonca, Fernando López-Alvarez, Jackeline Agorreta, Irati Garmendia, Luis M. Montuenga, Juana M. García-Pedrero, Juan P. Rodrigo

Open Access Original Article

Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model

Philipp Metzger, Sabrina V. Kirchleitner, Daniel F. R. Boehmer, Christine Hörth, Angelika Eisele, Steffen Ormanns, Matthias Gunzer, Maciej Lech, Kirsten Lauber, Stefan Endres, Peter Duewell, Max Schnurr, Lars M. König

Original Article

A TLR4–TRIF-dependent signaling pathway is required for protective natural tumor-reactive IgM production by B1 cells

Allison M. Dyevoich, Nataya S. Disher, Marcela A. Haro, Karen M. Haas

Open Access Original Article

Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy

Laura A. Vitale, Li-Zhen He, Lawrence J. Thomas, Anna Wasiuk, Thomas O’Neill, Jenifer Widger, Andrea Crocker, Laura Mills-Chen, Eric Forsberg, Jeffrey Weidlick, Colleen Patterson, Russell A. Hammond, James Boyer, Crystal Sisson, Diego Alvarado, Joel Goldstein, Henry C. Marsh Jr., Tibor Keler

Open Access Original Article

Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions

Zhenyuan Dong, Wesley A. Cheng, D. Lynne Smith, Brian Huang, Tiantian Zhang, Wen-Chung Chang, Xiuli Wang, Stephen J. Forman, Larry W. Kwak, Hong Qin

Original Article

NKG2D-Fc fusion protein promotes antitumor immunity through the depletion of immunosuppressive cells

Po-Hao Feng, Brandon Lam, Ssu-Hsueh Tseng, Yu-Jui Kung, Emily Farmer, Max A. Cheng, Chien-Fu Hung

Research Report

Sex differences in the association between tumor growth and T cell response in a melanoma mouse model

Panshak P. Dakup, Kenneth I. Porter, Alexander A. Little, Hui Zhang, Shobhan Gaddameedhi

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.